F-star Expedites Its Transition to a Wholly-Owned Portfolio Strategy
F-star, a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announced the reconfiguration of its immuno-oncology collaboration, established in 2017, with Merck KGaA, Darmstadt, Germany as it executes on its transition to a wholly-owned portfolio and builds scale and value as a world-class biopharmaceutical company.
Under the terms of the new agreement, F-star retains exclusive rights to develop and commercialise FS118, a clinical-stage tetravalent bispecific antibody. At the same time, Merck has exercised its option for one discovery stage programme and retains the right to option a second discovery programme from the 2017 original agreement. No financial terms of the agreement are being disclosed.
Eliot Forster, CEO of F-star, said: “This new agreement reflects our pivot to building a wholly-owned pipeline, that allows for rapid progress into the clinic and secures greater long-term value from our products. With full rights to FS118, we have an opportunity to accelerate the development of this first-in-class medicine for a group of targeted cancer patients. We are also pleased to continue our long-term collaboration with Merck KGaA, Darmstadt, Germany by advancing assets from F-star’s Modular Antibody Technology TM into their pipeline.”
FS118 is a potential first-in-class tetravalent bispecific antibody for the treatment of cancer, developed to overcome tumour evasion mechanisms promoted by two molecules (LAG-3: Lymphocyte-Activation Gene 3 and PD-L1: Programmed Death-Ligand 1) with the potential to restore the natural ability of the immune system to fight cancer(1). Initiated in April 2018 under F-star’s sponsorship, the Phase I trial (NCT03440437) continues as originally planned and is expected to read out during 2020.
- ENDS -
About F-star
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for cancer patients.
Find out more at www.f-star.com. Connect with us via LinkedIn and Twitter
About FS118
Currently in a Phase I trial at four clinical sites in the United States, FS118 is a potentially first-in-class medicine for the treatment of resistant and refractory cancer. This tetravalent, bispecific antibody is developed to overcome tumour evasion mechanisms promoted by two highly immuno-suppressive molecules: LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1). By simultaneously blocking both inhibitory pathways, FS118 has preclinically demonstrated a potent anti-tumour growth activity(1) as well as a highly differentiated mechanism of action(2) when compared to checkpoint monotherapies alone or in combinations.
In April 2018, a Phase 1 clinical study started in patients who have progressed on or after a prior PD-1/PD-L1 containing therapy. Information about the trial is available on clinicaltrials.gov NCT03440437. FS118 is manufactured at 2000L scale using standard mAb manufacturing processes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190513005894/en/
Contact information
For investor enquiries
Lindsey Trickett
VP
Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
For media enquiries
Pierre Peotta
Communications
Manager
+44 (0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
Consilium Strategic Communications
Chris Gardner, Sue
Stuart, David Daley
Tel: +44 (0)20 3709 5700
E-mail:
F-star@consilium-comms.com
US
Catherine London, US President
Tel: +1 917-763-2709
E-mail:
F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Slate Asset Management Announces Partner and Managing Director Promotions10.12.2025 15:00:00 EET | Press release
Slate Asset Management (“Slate”), a global alternative investment platform focused on essential real estate and infrastructure, today announced three senior leadership promotions, effective January 1, 2026. Molly Mahoney has been elevated to Partner, and John Murray and Sayed M. Alaali have been promoted to Managing Directors. “Molly, John, and Sayed have demonstrated outstanding dedication, skill, and leadership over the years and each has contributed meaningfully to Slate’s reputation as a proven investor and a trusted partner to leading global institutions,” said Brady Welch, Co-Founding Partner at Slate. “We are very pleased to welcome them to the highest ranks of our firm’s leadership.” Blair Welch, Co-Founding Partner at Slate, added: “In a year of significant growth, these individuals have consistently delivered exceptional outcomes for Slate’s clients, partners, and communities. They are unwavering in their commitment to excellence, integrity, and teamwork, and we look forward
Kingswood Capital Management Enters Into a Definitive Agreement to Acquire Safran Passenger Innovations10.12.2025 15:00:00 EET | Press release
Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) announced today that it has entered into a definitive agreement to acquire Safran Passenger Innovations (“SPI” or the “Company”) from Safran, an international high-tech company operating in the aviation, defense, and space markets. SPI is a leading global provider of in-flight entertainment and connectivity solutions for airlines and airplane manufacturers worldwide. Matt Smith will continue to serve as SPI’s CEO, and the entire SPI leadership team will remain in place. The transaction is expected to close early next year, subject to customary legal and regulatory requirements. Headquartered in Brea, California, SPI created and designed an award-winning in-flight entertainment and connectivity platform known as RAVE, recognized for its intuitive design, reliability, and innovative approach. Kingswood’s acquisition of SPI is driven by a shared vision of positioning the company to deliver transformative, next-ge
Armis Partners with KODE Labs and IntelliBuild to Streamline Security Operations Across the Building Management Lifecycle10.12.2025 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced a strategic partnership with KODE Labs and IntelliBuild to help organizations unify cybersecurity, operational intelligence and governance for building lifecycle management. The joint offering combines Armis’ continuous asset intelligence with KODE Labs’ performance trends and analytics, which are then operationalized by IntelliBuild’s governance and reporting. By translating accurate, verified intelligence into accountable action, organizations can streamline the operations of building management systems – from thermostats, lighting and badge readers to elevator controllers and security cameras – and proactively strengthen their cyber defenses. “To achieve real security in the new age of connected environments, you must have comprehensive, real-time protection across the entire attack surface,” said Nadir Izrael, CTO and Co-Founder at Armis. “This integration addresses the growing complexity, risk and fragmentati
FiRa Unveils New Membership Tier to Fuel Industry Growth10.12.2025 15:00:00 EET | Press release
FiRa® Consortium is expanding its membership structure with a new Associate tier that opens the door to broader industry involvement. With new revenue-based pricing, organizations of all sizes can now more easily help shape the future of precise, secure wireless experiences. By reducing cost-related barriers and expanding access to FiRa resources, this new tier opens the door for innovators, developers, and emerging players to contribute to the next generation of wireless capabilities. The updated structure gives companies a more flexible and accessible path to Associate membership: $7,500 USD for companies with annual revenue below $50 million USD $30,000 USD for companies with annual revenue above $50 million USD The refreshed Associate tier maintains all existing benefits, including participation in FiRa Working Groups, access to specifications, engagement in FiRa Plugfests, product certification opportunities, and eligibility to apply as a FiRa Authorized Test Lab. These opportunit
QuantrolOx Unveils VIDYAQAR — the World’s First True Open-Architecture Quantum Platform for Education, Research, Testing and Benchmarking10.12.2025 14:29:00 EET | Press release
QuantrolOx today announced a major milestone in quantum technology with the launch of VIDYAQAR, the world’s first True Open-Architecture Quantum Platform designed specifically for education, research, testing, and benchmarking. The system was unveiled today in India and will be available globally in the first half of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210668898/en/ VIDYAQAR - A complete quantum platform with cryogenics, control hardware and QPU - powered by Quantum EDGE. The name VIDYAQAR derives from the Sanskrit Vidyākar, meaning “causing wisdom, giving knowledge or science”—a perfect reflection of the platform’s mission to widen access to advanced quantum hardware and accelerate innovation. A Complete, Open and Scalable Quantum Platform VIDYAQAR is a connected, fully open-architecture superconducting quantum system that brings together: CryogenicsControl electronicsQuantum Processing Unit (QPU)Integra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom